Heart failure medicine recommended for EU approval 'Novartis'
|
11:31:00 PM |
No Comments |
Novartis AG's new heart failure medicine, Entresto, has been recommended for approval in Europe by a review body, the company said on Friday.
The approval by the Committee for Medicinal Products for Human Use puts Entresto on track to be approved for heart failure and reduced ejection fraction (HFrEF) patients across Europe likely by year-end, the company said.
Pending final approval by the European Commission, Entresto will be available for the treatment of adult patients with symptomatic chronic HFrEF, the company said.
Related Posts:
According to a new study,monkeys are drawn to brands with sexy advertising
Banking finally gaining foothold in Africa, in one chart- US state saved $240 million in health care spending
- America is as guilty as Russia when it comes to election meddling.
Dying cash in Sweden helicopter bank robbery helps explain.
